Michel Dahan - Mar 1, 2023 Form 4 Insider Report for Akebia Therapeutics, Inc. (AKBA)

Role
SVP, Chief Operating Officer
Signature
/s/ Carolyn Rucci, attorney-in-fact for Michel Dahan
Stock symbol
AKBA
Transactions as of
Mar 1, 2023
Transactions value $
-$17,912
Form type
4
Date filed
3/3/2023, 07:01 AM
Previous filing
Mar 1, 2023
Next filing
May 16, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKBA Common Stock Sale -$7.07K -8.06K -2.78% $0.88 282K Mar 1, 2023 Direct F1
transaction AKBA Common Stock Sale -$9.19K -10.5K -3.72% $0.88 271K Mar 1, 2023 Direct F2
transaction AKBA Common Stock Sale -$1.65K -1.88K -0.69% $0.88 270K Mar 1, 2023 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2022.
F2 This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2020.
F3 This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the performance-based restricted stock units that were previously reported for the Reporting Person on a Form 4 filed on March 18, 2021.